Project Grant R43CA243927

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,924 to Convergent Engineering, Inc. to develop a prototype decision support system for personalized mechanical ventilation care. The system aims to simplify the use of esophageal pressure measurements to optimize ventilator settings and prevent complications for ventilated patients. The project has two key objectives: 1) Building a...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,564,220 to The Trustees of the University of Pennsylvania to develop an imaging-compatible ex vivo lung perfusion (EVLP) system capable of obtaining structural, functional, and metabolic biomarkers in donor lungs. The project aims to utilize these biomarkers to non-invasively assess donor lungs with common defects, apply injury-specific treatment strategies...

This $189,332 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to transform the delivery of interstitial lung disease (ILD) care through remote patient monitoring and artificial intelligence-powered clinical decision support. The key products and services to be delivered under this 5-year grant include: Identifying provider and health system barriers to adopting a remote patient monitoring...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $666,609 to North Carolina State University to develop and demonstrate the feasibility of lung quantitative ultrasound (LQUS) for assessing the severity of pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The goal is to create a real-time, non-invasive, point-of-care method to monitor these lung conditions,...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $260,586 to the University of Wisconsin-Madison to develop a novel positron emission tomography (PET) probe optimized for non-invasive monitoring of disease activity and treatment response in idiopathic pulmonary fibrosis (IPF). The goal is to leverage the team's expertise in matrix biology, small animal imaging, and probe development to optimize a...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, provides $812,189.00 to conduct research on using CT imaging to screen for and subtype pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD). The 4-year project aims to identify CT imaging features that can predict the presence of pulmonary...

This Project Grant award of $306,530, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to develop and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. The device will enable free-breathing dynamic cardiopulmonary function imaging without the need for patient compliance with extended breath-hold maneuvers. The...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $742,810 to the University of Virginia to develop hyperpolarized gas MRI (HGMRI) signatures for detecting and monitoring acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, treatment response, and single-cell RNA-sequencing data to enhance early...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500.00 to Brigham & Women's Hospital Inc. from February 1, 2025 to January 31, 2027. The project aims to develop and validate a quantitative marker of pulmonary microvascular injury using an AI-based algorithm to assess vascular perfusion from single energy non-contrast CT scans. This marker will be used to investigate the relationship between pulmonary...